Media headlines about Affymetrix (NASDAQ:AFFX) have been trending positive this week, according to Accern Sentiment. Accern identifies positive and negative media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Affymetrix earned a news impact score of 0.35 on Accern’s scale. Accern also gave press coverage about the scientific and technical instruments company an impact score of 46.5166188012407 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Shares of Affymetrix (NASDAQ:AFFX) remained flat at $14.01 during trading on Monday. Affymetrix has a 1-year low of $8.28 and a 1-year high of $16.15. The firm has a 50 day moving average price of $14.15 and a 200 day moving average price of $11.20.
ILLEGAL ACTIVITY WARNING: “Affymetrix (AFFX) Earns Coverage Optimism Rating of 0.35” was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this report on another publication, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this report can be read at https://stocknewstimes.com/2017/08/28/affymetrix-affx-earns-coverage-optimism-rating-of-0-35.html.
Affymetrix Company Profile
Affymetrix, Inc (Affymetrix) is a provider of life science products and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein and cell level. The Company operates through two business segments: Affymetrix Core and eBioscience. The Affymetrix Core segment focuses on the development, manufacture and commercialization of systems for genetic analysis in the life sciences, agricultural biotechnology (AgBio) and diagnostic industry.
Receive News & Ratings for Affymetrix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affymetrix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
